A director at PTC Therapeutics Inc sold 11,220 shares at 56.159USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Another Bear Market Rally Brewing? In last week's Compass (Sept. 27) we discussed our belief that the market indexes could see a bounce or pause in selling, citing numerous oversold indexes/Sectors that were testing critical supports, including 3636 on the S&P 500, $269 on the Nasdaq 100 (QQQ), and $162 on the Russell 2000 (IWM). Sector and index supports held, and early indications suggest a bear market rally is brewing, and potentially that the lows are in for this bear market, helped by shor...
The independent financial analyst theScreener just awarded an improved star rating to PTC THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 4, 2022,...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, wh...
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into PTC Therapeutics, Inc. (NasdaqGS: PTCT). On February 23, 2016, PTC revealed that it had received a Refuse to File (“RTF”) letter from the U.S. FDA on its New Drug Application (“NDA”) for its primary drug Translarna stating that it was “not sufficiently complete to permit a substantive review,” which meant that it was...
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into PTC Therapeutics, Inc. (NasdaqGS: PTCT). On February 23, 2016, PTC revealed that it had received a Refuse to File (“RTF”) letter from the U.S. FDA on its New Drug Application (“NDA”) for its primary drug Translarna stating that it was “not sufficiently complete to permit a substantive review,” which meant that it was...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.